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Abstract
Background: Cerebral palsy (CP) is the most common pediatric disease to cause motor disability. Two common
symptoms in CP are spasticity and contracture. If this occurred in the ankle plantar flexors of children with CP, it will
impair their gait and active daily living profoundly. Most children with CP receive botulinum toxin type A (BoNT-A)
injection to reduce muscle tone, but a knowledge gap exists in the understanding of changes of neural and
non-neural components of spasticity after injection. The purpose of this study was to determine if our device
for quantitative modified Tardieu approach (QMTA) is a valid method to assess spasticity of calf muscles after
botulinum toxin injection.
Methods: In this study, we intended to develop a device for quantitative measurement of spasticity in calf
muscles based on the modified Tardieu scale (MTS) and techniques of biomedical engineering. Our QMTA measures
the angular displacement and resistance of stretched joint with a device that is light, portable and can be operated
similar to conventional approaches for MTS. The static (R2), dynamic (R1) and R2-R1 angles derived from the reactive
signals collected by the miniature sensors are used to represent the non-neural and neural components of
stretched spastic muscles. Four children with CP were recruited to assess the change in spasticity in their
gastrocnemius muscles before and 4 weeks after BoNT-A injection.
Results: A simulated ankle model validated the performance of our device in measuring joint displacement and
estimating the angle of catch. Data from our participants with CP showed that R2 and R2-R1 improved significantly
after BoNT-A administration. It indicates both neural and non-neural components of the spastic gastrocnemius muscles
improved at four weeks after BoNT-A injection in children with CP.
Conclusion: Our device for QMTA can objectively measure the changes in spasticity of the gastrocnemius muscle in
children with cerebral palsy after BoNT-A injection.
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Background
Cerebral palsy (CP) is a group of permanent disorders
attributed to a non-progressive insult to the developing
fetal or infant brain [1, 2]. The type of brain damage
observed in children with CP will lead to abnormal de-
velopment of movement and posture which results in
physical disability and limitations in activity [3–5].
Spastic type is the most common type of CP, which
comprises about 80 % of reported cases [1, 2]. Although
the brain injury caused by CP is non-progressive, the level
of impairment related to spasticity on the musculoskeletal
system is progressive and may result in deformity and
contracture [3–5]. Long-lasting spasticity will inevitably
change the biomechanical properties of muscles and
soft tissues around the joints. Gradual deterioration of
function such as ambulation may arise from changes in
soft tissues, which is thought to be non-neural origin
[6]. Among current therapies, botulinum toxin type A
(BoNT-A) injection which blocks acetylcholine release
at the neuromuscular junctions [7] has been one of the
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optimal options for children with spastic CP to reduce
muscle tone of the lower leg and to improve the gait
[8]. BoNT-A decreases spasticity at the level of body
structure and function. It may lead to improved execution
of walking activity and participation in daily life as demon-
strated in improved levels of activity and participation
based on the World Health Organization (WHO)’s inter-
national Classification of Functioning, Disability, and
Health (ICF) [9, 10]. To comprehensively understand
the effects of BoNT, from body function to activity and
participation, further studies are required.
In this pilot study, BoNT-A injections were used to
determine the sensitivity of our device to detect changes
in spasticity. We want to know the effects of BoNT-A
combined with rehabilitation programs on the neural and
non-neural components of spastic muscles. However,
there is only limited literature documenting these effects.
According to the definition of Lance [11], spasticity is
a motor disorder characterized by a velocity-dependent
increase in tonic stretch reflexes with exaggerated ten-
don jerks. Based on the consensus from the Task Force
on Childhood Motor Disorders [12], spasticity is defined
as one type of hypertonia in which one or both of the
following signs are present: (1) resistance to externally
imposed movement increases with increasing speed of
stretch and varies with the direction of joint movement,
and/or (2) resistance to externally imposed movement
rises rapidly above a threshold speed or joint angle. The
effect of BoNT on spasticity is most commonly evalu-
ated with clinical scales such as modified Ashworth scale
(MAS) [13] and modified Tardieu scale (MTS) [14, 15].
The MAS uses an ordinal scale to grade spasticity [16]
and is the most common and convenient method to use
in the clinical setting [17]. MAS assesses spasticity based
on the resistance felt subjectively during passive stretch.
However, the perceived resistance may be caused by
neural and/or biomechanical origins, which MAS might
fail to distinguish [18, 19]. In addition, the MAS has
been criticized for their low reproducibility and poor ac-
curacy in the previous review articles because it did not
take into account the velocity-dependent aspect of spas-
ticity [18, 19]. On the other hand, Boyd et al. developed
the MTS as a clinical measurement for spasticity of
lower extremities in children with cerebral palsy [14, 15].
The concepts used in MTS cover the velocity-dependent
properties of spastic muscle as both slow and fast
stretches are evaluated [20]. MTS utilizes manual stretch
to measure the R2 and R1 angles of spastic muscle in the
knee and ankle joint. R2 and R1 angles are defined as the
first position that the examiner feels resistance when slow
and fast stretch were applied to the joints respectively. R2
angle is generally accepted as the measurement of non-
neural component of the stretch joint [14, 20]. In the
neural component, the difference between R2 and R1 is
more important than the individual values of R1. The dy-
namic component defined as R2 minus R1 (R2-R1), can
be considered as the neural component of spastic muscles
[20]. However, when measuring the angles of R1, R2 and
R2-R1 with the universal goniometer, many factors such
as stretched velocity and the reactive resistance during
stretches may be overlooked. Furthermore, determining
MTS angles with the goniometer might be imprecise due
to errors of joint repositioning [21, 22]. If the joint dis-
placement and reactive resistance can be measured quan-
titatively during MTS evaluation, then the response to
BoNT treatment for spastic muscles may also potentially
be quantified.
Quantitative MTS approach was first introduced by
van den Noort et al. in 2009 [23]. They measured joint
displacement by using commercial inertial sensors for
manual stretch. The angle of catch (AOC) can be derived
from the abrupt cessation of the joint displacement during
fast stretch [22]. In recent years, Bar-On et al. have
successfully used the MTS-like concept to develop an
instrumented manual spasticity assessment for calf
spasticity quantification [24, 25]. By using the combination
of inertial and force sensors, the joint displacement and
the reactive resistance can be recorded simultaneously
during slow and fast stretch on the spastic muscle. The
AOC was then derived from the joint displacement data
according to the biomechanical or neurophysiological in-
formation such as angular deceleration, change of force or
electromyography (EMG) signal. They found the MTS-
like quantitative approach provides moderately high reli-
ability and clinically relevant measures for calf spasticity
[25]. Compared to motor-driven quantification approach
[26, 27], the advantage of these manually-applied approach
is the involvement of an experienced evaluator to improve
patient compliance during the study. However, the trad-
itional method using the instrumented manual approach
requires the attachment of sensors on a device such as a
dynamic orthosis around the joint [20, 25]. This may
reduce patient compliance especially during evaluation of
pediatric patients. Fixation of limbs around joints is un-
necessary with our device. In our study, we tried to reduce
the size of our sensors and apply it in a clinical manner we
use every day in clinics (Fig. 1(a) and (b)). Furthermore,
few studies have used the manually-applied quantitative
approach to analyze the therapeutic reactions of BoNT in-
jection on both neural and non-neural components of
spastic calf muscles in patients with CP.
There were two main objectives of our study. First, we
developed a hand-held device for objective measurement
of calf muscle spasticity to improve record of angles with
the traditional MTS. The measuring device was built to
be used with the same manner and rationale of MTS,
which we called quantitative modified Tardieu approach
(QMTA). We also used a simulated ankle model to
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validate the recording of joint displacement and reactive
resistance before applying it to children with CP. Second,
we aimed to use QMTA in children with cerebral palsy to
study the changes of neural and non-neural components
of spastic calf muscle after BoNT-A injection. We
hypothesize that both neural and non-neural components
of the spastic calf muscle will improve at four weeks
after BoNT-A injection by measuring the quantitative
parameters with our QMTA.
Methods
The rationale for modified Tardieu scale to determine the
angles related to spasticity is illustrated in Fig. 1. In conven-
tional MTS approach [14, 15], the examiner holds the upper
part of the foot and utilizes a slow and fast stretch to assess
the range of motion (ROM) for the ankle joint (Fig. 1 (a)).
To differentiate the contributions of gastrocnemius and so-
leus for spasticity in calf muscles, we routinely test ROMs of
ankle with the knee placed in flexion and extension. To
examine the resistance of gastrocnemius, the hip and knee
of participants were maintained in extension and the ankle
joint was moved from maximal plantarflexion to maximal
dorsiflexion. The same procedures were performed for test-
ing the soleus, except the ipsilateral hip and knee were flexed
at 90°. All four participants in our trial received BoNT-A
injection to the gastrocnemius. The hips and knees of
participants were maintained in extension when we
performed the R1 and R2 examinations of ankle joints.
The end ROM is determined when the examiner feels the
resistance barrier of the joint, which can be defined as the
peak resistance during stretch (Fig. 1 (c)). In traditional
MTS setup, the examiners measure the displacement
angle with a universal goniometer to find the R1 or R2
angle. Our QMTA is designed to place a sensing device
between the patient’s foot and the examiner’s hand to
record the resistance and the displacement during
manual stretches (Fig. 1(b)). After determining the peak
resistance, we can find the corresponding displacement
angle of the ankle joint for R1 and R2 (as shown in
Fig. 1(c)-(d)).
System setup
An integrated system with angular velocity and resistance
measurement was developed to determine the static (R2)
and dynamic (R1) angles of spasticity during manual
stretches (as shown in Fig. 2). Details of the major compo-
nents are described as following.
The device used for spasticity measurement is inte-
grated as a hand-held device with dimensions of 5 cm ×
5 cm × 3 cm (length x width x height) and with weight
of 125 g (Fig. 2(a)). Upon stretching of the spastic muscles,
the sensing device will be placed firmly in contact with the
ball of foot and the angular velocity of that foot will be re-
corded along with the reactive resistance produced by the
Fig. 1 Rationales of spasticity measurement for modified Tardieu scale (MTS) and our quantitative modified Tardieu approach (QMTA). a Conventional
MTS approach. b Our QMTA approach. c Expected curves of resistance during a manual stretch. d Expected curves of displacement during slow or fast
stretches. Both curves of (c) and (d) are derived from a fast stretch on a spastic ankle joint of a patient with cerebral palsy
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stretched foot. As showed in Fig. 2(a) and (b), a one-axis
rate gyroscope module (2.5 cm × 1 cm × 1 cm; ADXRS300,
ADI Co., Ltd) was implemented in the lower part of the de-
vice to sense the angular velocity of the stretched foot. By
using the integration algorithm, the displacement of ankle
joint can be derived from the angular velocity signal. Fur-
thermore, a miniature load cell (1 cm diameter and 0.3 cm
height; LBS-100, Interface Co., Ltd) was mounted at the
center of the lower part. Since the sensing area of the load
cell is higher than the surface of the lower part of the de-
vice, the reactive resistance from the stretched foot can be
transmitted to the load cell and be recorded continuously.
As shown in Fig. 2(c), a laptop computer was used to
administer the data acquisition and serve as the graphical
user interface (GUI). The measured velocity and resistance
signals were acquired by the computer through a 12-bit
A/D converter (DAQCard-6036E, National Instruments
Inc.) at a sampling rate of 100 Hz for storage and display
of the data. A customized LabVIEW-based program
(Version 7.1, NI, Inc.) with an integrated user interface
provides the setting of parameters, display of data, and
gathering of the signals during the experiment. Further-
more, the examiner can consult the computer screen in
order to visualize the resistance and velocity of the applied
stretch to help him/her maintain similar maneuvers
among trials.
Validation of measurement system
Before we applied the QMTA for clinical patients, the
performance of the measurement system was first vali-
dated. For convenience, we made a simulated foot model
with a movable joint to do all the validation tests (as
shown in Fig. 3). The simulated model was made by a
child shoe filled with casting to simulate the weight of
real child foot. A shaft was mounted on the rotation axis
of the model and was connected to the platform via a
bearing seat. The movable range of the foot model was
0°~70° (assumed maximal movable range of CP subjects)
and the end range (70°) is limited by a steel cord. The
range was calibrated with a general inclinometer before
all the validation tests (Fig. 3(c)&(d)).
To validate the performance of our gyro chip module
in the measurement of angular velocity and displacement
during stretches, we used a commercial gyro product
(Range: +/−600°/s, 2.7x2.4 x2.4 cm; Model 11206 AC,
Summit Co., Ltd) for comparison. As shown in Fig. 3(e),
the examiner held the sensing device (along with com-
mercial gyro) and stretched the foot model under two
self-selected speeds (slow and fast). The examiner was
instructed to move the model from the movable range
0° to 70° and to cease the stretch when he felt resistance.
Four to-and-fro stretches for each speed were performed
continuously and the signal of both gyros were recorded
and analyzed after. Both gyro signals were filtered (15Hz
low-pass filter) and integrated (trapezoid approach) to ob-
tain the displacement information with Matlab software.
Both the angular velocity and displacement were com-
pared between two gyros with the correlation coefficient.
The averaged error percentage was also calculated for
angular displacement to compare the performance of
displacement measurement. The error percentage (EP)
of the gyro module at each data point was defined as:
Fig. 2 The spasticity measurement system for the quantitative modified Tardieu approach. a Mechanical parts of the sensing device. The upper
and lower parts were connected via four sliding tracks to decrease the friction during compression. b A gyroscope was used to record angular
velocity and was applied during ankle displacement to identify the angular displacement. A miniature load cell (load button) was used to record
resistance during stretch. c The hand-held sensing device recorded and sent signals (angular velocity and resistance) to a computer via an A/D
converter during ankle stretch
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EP %ð Þ ¼ DGyro1– DGyro2
 
=DGyro2  100 ð1Þ
where DGyro1 and DGyro2 represents the angular displace-
ment of QMTA device and commercial gyro at one
point of time respectively.
The same foot model was used to test the feasibility of
R1 and R2 estimation by the displacement and resistance
signals of the QMTA device (Fig. 3(f )). The foot model
was stretched toward the end-range of 70° from 0°
with both slow and fast stretches. The examiner was
instructed to move the model five times for each vel-
ocity and to stop each stretch when he felt the resist-
ance. Both gyro and resistance signals were filtered
(15Hz low-pass filter) and the filtered gyro signal was
integrated (trapezoid approach) to get the displacement
data. As shown in Fig. 1(c) and (d), peak of resistance was
marked and was used to find the resistance angles (R1 and
R2) from the derived displacement. For a mechanical joint
model, the approximation of static angle R1 and dynamic
angle R2 was assumed.
Subjects recruitment for clinical application
We used our QMTA device and approach to evaluate
the effects of BoNT-A injection on spastic calf muscles.
Four children with cerebral palsy (CP) were recruited in
our study. All subjects were diagnosed and evaluated by
a qualified physiatrist before participation. The following
Fig. 3 The simulated foot model for validation tests of our measurement system. a & b The simulated model was designed to rotate around the
bearing seat. c & d The movable range was set and calibrated as 0° to 70°, in a range similar to the real foot available range. The resting position
(about 40° elevation from the platform) is defined as 0° of the model. e We attached a commercial gyro along with our device to record the
angular velocity simultaneously. f Test of the feasibility of R1 and R2 estimation by the displacement and resistance signals of QMTA device
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procedure of QMTA evaluation was also done by the
same physiatrist. The parents of subjects were told the
procedures and the necessary information of the experi-
ment. They signed the informed consent before entering
the study. The study protocol was approved by the local
Ethics Committee and Institutional Review Board (refer-
ence number EMRP04098N). All subjects were diagnosed
as spastic type CP with involvement of one or both lower
limbs. The subjects did not receive leg surgeries before
and during the experimental period. All recruited subjects
cooperated well during the injection and the evaluation
period. OnabotulinumtoxinA (Botox Allergan, CA) injec-
tions were performed smoothly for all patients, with the
total dosage of 15 unit/kg. The detailed information of
subjects is summarized in Table 1.
The examiner was trained to use the device and his
stretch maneuvers were validated before evaluation.
The examiner was instructed to stretch the foot with
usual manner of MTS and to cease the stretch when he
felt the resistance of end range. For the clinical evalu-
ation setup, the foot was first placed on a wedge to set
the initial stretch angle 40° or 50° of plantar flexion
from neutral position (Fig. 2(a)). The examiner first
stretched the spastic ankle with slow-velocity and then
stretched with fast-velocity to avoid the effects of over-
active stretch reflexes. At least six stretches for each
velocity were made during an evaluation course. To
provide a consistent initial position of ankle joint to
minimize the error of displacement due to drift, at least
3 s was reserved between each stretch cycle to ensure
the gyroscope signal had returned to a stable baseline.
Any stretch that did not follow the above instructions
was considered invalid and was discarded online. Since
the evaluation was done in the outpatient setting, the
entire evaluation process took less than ten minutes for
each patient. Only five of six stretches were selected to
further process with the same method as described
previously.
All subjects were evaluated on the day before BoNT-A
injection and four weeks after injection when he/she
returned to the outpatient department. The modified
Ashworth scale (MAS 0–5) of the tested limb was also
collected. Routine rehabilitation program including
physical and occupational therapy continued during the
four-week experimental period.
Data analysis
The recorded velocity and resistance signals were offline
processed with Matlab program. With derived displace-
ment and resistance during one stretch cycle, the peak of
resistance was found and the corresponding displacement
angle was considered as the R1 or R2 angle for fast and
slow stretch respectively. For analysis of BoNT-A effects
on spasticity of calf muscle, we compared MAS, R1 angle,
R2 angle, and difference between R2 and R1 angle at base-
line and four-week after injection with Wilcoxson signed-
rank test. To understand the stretch manners of QMTA
evaluation, peak velocities of both slow and fast stretches
were also compared with Wilcoxson signed-rank test.
Results
Comparison with commercial product
As shown in Fig. 4(a), angular velocity signals from our
device and commercial gyro showed similar results with
a correlation coefficient of 0.9957. When we derived the
angular displacement of both gyros by integration, both
results revealed the drift effect as time proceeded
(Fig. 4(b)). If we use the commercial gyro as the reference,
the averaged error percentage during the 70-s test period
was 4.36 %. However, if we calculated the displacement of
each stretch individually, the error percentage of measured
displacement ranged from 0 % to 1.73 % for all stretch
trials which is a direct result of the noisy signal.
R1 and R2 measurements with foot model
Displacement and resistance curves during five slow and
fast stretches performed on the simulated joint model are
shown in Fig. 5. The parameters R1 and R2 of displace-
ment were derived according to the peak of corresponding
resistance in each stretch (green dashed lines in Fig. 5). In
this validation trial, the averaged peak velocities of slow
and fast stretches were 240.6° /s and 51.7° /s respectively.
The averaged R1 and R2 parameters for slow and fast
stretches were 70.6° and 69.9° respectively. Finally, the
average R2-R1 was −0.6°. For a mechanical joint model,
the approximation of static angle R1 and dynamic angle
R2 was confirmed.
Effect of BoNT-A injection
Table 2 shows the outcome measures before and 4 weeks
after administration of BoNT-A. Evaluation of spasticity
Table 1 Profile of participants
Subject no. Sex Diagnosis GMFCS Spastic leg Age (y/o) Height (cm) Weight (kg) Initial angle (R/L) (o)
S1 Male Spastic diplegic CP III R/L 8 110 22 40/40
S2 Female Spastic diplegic CP III R/L 5 114 12 40/40
S3 Male Spastic triplegic CP III R/L 7 114 26 40/50
S4 Female Spastic hemiplegic CP II R 6 100 18 40
CP Cerebral Palsy, GMFCS Gross Motor Function Classification System, R/L the right and left side
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by MAS revealed that there was one grade of improve-
ment in participants 1, 3 and 4; there was a two-grade im-
provement in participant 2. MAS improved significantly
after BoNT-A injection. The mean of R1 did not differ sig-
nificantly after BoNT-A injection. Improvement of 7.4°
was found for the mean of R2 after injection. The angle of
R2-R1 also increased significantly after injection.
Discussion
In the study, we have developed a miniature device that
can be used as a quantitative measurement for spasticity
of calf muscle in children with CP. This novel device
along with a miniature gyro sensor and a load cell has
the capacity to record joint displacement and resistance
by routine clinical approaches and can be used for the
evaluation of spasticity. As shown in Fig. 1(b), the port-
able device can be used in conjunction with the MTS
approach. With the data of joint displacement and re-
sistance, resistance angles can be derived to retrieve R1,
R2, and the difference between R2 and R1 of spastic
muscles in a more objective manner. The stretch man-
euver of our quantitative modified Tardieu approach
Fig. 4 Gyro performance of displacement measurement between our device and commercial product (comm. gyro). a Angular velocity signals
(with 15Hz low-pass filtering) during four slow and four fast stretches. The signals were almost identical with very good correlation (CC = 0.9957).
b The derived displacement signals both showed a drift phenomenon (an upward trend was noted). The green arrows indicated the start position of
each stretch and were used as a reference to calculate each stretch displacement. c For all stretch cycles, the displacement from our gyro was very
close to the commercial gyro with a maximal error percentage of 1.7 %
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(QMTA) follows the same maneuver of modified Tardieu
scale used in clinic. The stop points of R1 and R2 is de-
cided by the same evaluator when he feels the resistance.
The validity and reliability of MTS had been established in
previous studies [14, 20]. Under this circumstance, our de-
vice only needs to evaluate its accuracy in measurement of
the joint angles. Validation test of the device showed good
performance in displacement measurement (Fig. 4) and
resistance angle (Fig. 5). The problem of the drift
phenomenon in measurement of joint displacement
with gyroscope sensor [28] can be minimized if we keep
the gyro signal stable before each stretch and carefully
choose the starting position of each stretch (Fig. 4(c)).
The results of our validation suggested that our QMTA
might be feasible to quantitatively measure the response
of BoNT-A injection on spastic calf muscle of children
with CP. Compared to previous studies using inertial
sensors to determine the catch angles during stretches
[22–25], our approach used fewer constraints such as
orthoses or fixators on patients and therefore had bet-
ter compliance. In a clinical setting, less interference
on the subject might be necessary. The advantage of
our QMTA device over the clinical scales includes its
convenience for clinician to use at bed-side and in
clinic to objectively investigate the effects and the optimal
dosage of BoNT for patients with cerebral palsy.
Fig. 5 Displacement and resistance curves of foot model testing with five slow and fast stretches. The green dashed lines indicate the peak of
resistance curve and were used to find the parameters of R1 and R2. Displacement of joint model for slow and fast stretches are shown in (a)
and (c) respectively. Corresponding resistance curves for slow and fast stretches are shown in (b) and (d) respectively
Table 2 Changes of MAS and QMTA parameters after four weeks
of BoNT-A injection from seven spastic calf muscles of 4 subjects
with CP
Subject R/L Weeks MAS aR1 aR2 aR2-aR1
S1 R 0 4 35.2 48.8 13.6
4 3 34.9 55.1 20.2
L 0 4 42.3 55.7 13.4
4 3 32.9 54.0 21.1
S2 R 0 4 45.5 59.4 14.0
4 2 53.8 68.8 15.0
L 0 4 47.0 60.3 13.3
4 2 52.7 78.1 25.4
S3 R 0 4 33.5 53.7 20.2
4 3 46.0 60.9 14.9
L 0 3 47.8 58.3 10.5
4 2 47.5 61.1 13.7
S4 R 0 4 32.4 44.1 11.7
4 3 35.6 54.4 18.8
Week 0 Mean ± SD 3.9 ± 0.4 40.5 ± 6.7 54.4 ± 6.0 13.8 ± 3.1
Week 4 2.6 ± 0.5 43.3 ± 8.8 61.8 ± 8.9 18.4 ± 4.2
P value <0.001* 0.169 0.009* 0.036*
MAS Modified Ashworth Scale, QMTA Quantitative Modified Tardieu Approach,
CP Cerebral Palsy, R/L the right and left side, aR1 averaged R1, aR2 averaged
R2, aR2-aR1 averaged R2 minus averaged R1, SD Standard Deviation
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The MTS used R2, R1, and R2-R1 to measure the dif-
ferent components of spasticity in joints of children with
CP. Boyd et al. found a larger value of R2 minus R1 de-
notes more dynamic component which is more likely to
respond to the injection of BoNT-A [14]. Small differences
between R2 and R1 implies that more contributions are
coming from non-neural biomechanical components,
such as intrinsic stiffness. Slow velocity examination of R2
through passive joint ROM indicates the muscle length
controlled by neural and non-neural components. Our re-
sults showed significant improvements for the difference
between R2 and R1 after BoNT administration. This sug-
gests that spasticity was reduced at 4 weeks after injection
and this corresponded to the neurophysiological response
of treatment with BoNT occurring within four weeks [29].
R2 increased significantly at 4 weeks following BoNT in-
jection in our study. This was compatible with the findings
that Park and Kown had observed, which showed de-
creased muscle spasticity and decreased muscle stiffness
at 4 weeks after BoNT injection and intensive rehabilita-
tion treatment which was confirmed by a decrease in the
color-coded scale and an increase in the strain ratio using
dynamic sonoelastography [30]. Park and Kwon used
modified Ashworth scale (MAS) and real-time sonoelasto-
graphy (RTS) in their study to investigate the neural com-
ponent and the biomechanical component such as
intrinsic stiffness of gastrocnemius muscles after rehabili-
tation therapy with botulinum toxin A injection in spas-
tic cerebral palsy [30]. Their results demonstrated
decreased MAS score and reduced muscle stiffness
through RTS at 4 weeks after the intervention. It means
that both the neural component and the biomechanical
(non-neural) component improved after treatment with
simultaneous rehabilitation therapy and botulinum toxin
A injection. We assessed the intrinsic muscle stiffness of
gastrocnemius muscle by R2 changes in MTS after our
intervention. Our participants also received rehabilitation
therapy after administration with botulinum toxin A. As a
result, the findings from their study were consistent with
our results and supported similar conclusions. However,
Alhusaini et al. [31] found increased ankle ROM but
unchanged passive intrinsic muscle stiffness during low-
velocity stretches of the gastrocnemius in 16 children with
CP at 6 weeks after BoNT-A injection. As the maximal
response occurs within 4 weeks after administration of
BoNT-A [32], the different time point of follow-up may
account for various effects in above studies.
Some trials found that BoNT-A injection and other in-
terventions such as serial casting and stretching might
improve the non-neural components of hypertonia. Be-
sides, contradictory results exist for ROM gained in
ankle after administration with BoNT-A. In the assess-
ment of protocol for serial casting after botulinum toxin
injections to treat equinus in children with CP, Kelly
et al. found that improvements in the MTS were seen in
R1 and R2 values for dorsiflexion with both the knee in
extension and in flexion [33]. Their findings indicated
that both R1 and R2 could improve after administration
of BoNT-A and other intervention. Koman et al. con-
ducted a multi-center trial of 207 children with CP hav-
ing BoNT-A injections to the gastrocnemius muscles,
they found the active movement of ankle improved after
injection [34]. All the participants in our study received
routine rehabilitation programs such as strengthening and
ankle stretching after BoNT-A injection, with each patient
performing three, 30 min sessions per week for a total of
4 weeks. Therefore, our findings of improvements of R2-
R1, R2 and R1 are compatible with the results of above
studies.
On the contrary, previous studies have shown that the
effects of BoNT-A injection on ROM had a short dur-
ation and contractures continued to develop despite the
muscle tone had decreased after injection. The prospect-
ive long-term follow-up investigation by Tedroff et al.
demonstrated an increase of 4° to 7° in dorsiflexion
ROM in the calf of children with CP after BoNT injec-
tion [35]. However, the ROM decreased as soft tissues
reverted to their original status. As the participants were
only assessed at 4 weeks after injection in our study, we
may have failed to find the changes after 4 weeks in
these patients. This may explain the differences of our
findings as compared to the results of Alhusaini et al.
that was followed before and at 6 weeks after injection.
Some histological changes in the muscles had been re-
ported after BoNT-A injection in their study. Dodd et al.
found a shift in heavy-chain composition from faster to
slower isoforms in rat muscle after injection with BoNT-
A [36]. Legerlotz et al. also noted that BoNT-A injection
resulted in slower myosin heavy-chain isoform compos-
ition and reduced titin content by 18 % in the gastrocne-
mius muscles of juvenile rats [37]. These reactions after
BoNT administration may change the characteristics of
the muscle that account for what we saw in our results.
Further studies are necessary to illuminate the role of
BoNT-A in neural and non-neural components of pa-
tients with spasticity.
The physician involved in the assessment of angles via
QMTA in this study was satisfied with the tiny, convenient
and quick features of this device. The entire evaluation
process took less than ten minutes for each patient. It is
suitable for the routine assessment of spasticity in the
outpatient setting, especially for the children clients.
In the double-blind study investigating the effect of
BoNT-A, Sutherland et al. suggested that children under
4 years of age may have difficulty in cooperation during
the evaluations [38].
There are several limitations in our present pilot study.
First, we did not collect the EMG data from our subjects
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during stretches. EMG can be used to monitor the re-
laxation of stretched muscles [39] and to confirm the
presence of stretch reflexes during fast stretches [40]. It
may help the clinician decide the points of R1 and R2
more precisely. As our study was performed in the clin-
ical setting of an outpatient department, we tried to
minimize the time spent in the evaluation by omitting
other interventions such as EMG, to obtain a better
compliance of children with CP. In total, we spent less
than 10 min for QMTA evaluation of both legs in each
CP subject, which included communication, waiting and
the examiner completing the steps of QMTA we men-
tioned in section 2. Second, the sample size of subjects
was very small in this pilot study. More participants are
necessary for future studies. Furthermore, the follow-up
period should be longer to follow the long-term effect of
BoNT-A on neural and non-neural components of spastic
calf muscle.
Conclusions
Our quantitative Tardieu scale approach (QMTA) is feasible
to quantitatively measure the effect of botulinum toxin in-
jection for gastrocnemius muscle spasticity in children with
cerebral palsy. It may help clinicians decide the optimal
dosage of botulinum toxin type A for spasticity of calf
muscle in children with CP. This new device needs more
participants and longer follow-up periods in future studies.
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